reports
Option Care Health to Announce Third Quarter 2019 Financial Results an...
Option Care Health to Announce Third Quarter 2019 Financial Results and Host Conference Call BANNOCKBURN, Ill., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Option Care Health Inc. (NASDAQ: BIOS), the nation’s largest independent national provider of home and alternate site infusion services, today announced that the Company will release results for its third quarter ended September 30, 2019 on Wednesday, November 6, 2019 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call Details ...
BioScrip Announces Shareholder Approval of Merger with Option Care
BioScrip Announces Shareholder Approval of Merger with Option Care DENVER, Aug. 02, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the “Company”), the largest independent national provider of infusion and home care management solutions, today announced that its stockholders approved the proposals that are conditions to the proposed merger with Option Care at the Company’s special meeting of stockholders held earlier today. BioScrip’s merger with Option Care is expected to close on or about August 6, 2019. About BioScrip, Inc. BioScrip, Inc. is the largest ...
BioScrip Reports Second Quarter 2019 Financial Results
BioScrip Reports Second Quarter 2019 Financial Results DENVER, July 30, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its second quarter 2019 financial results. Second Quarter 2019 BioScrip Highlights Net revenue of $191.5 million, up 8.9% compared to $175.8 million in the second quarter of 2018.Gross revenue1 of $196.8 million, up 13.1% compared to $174.0 million in the prior year quarter.Net loss from continuing operations of $14.2 million, ...
Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Recomme...
Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend that BioScrip Stockholders Vote “FOR” the Transaction Proposals in Connection with the Proposed Merger with Option Care DENVER, July 22, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip"), the largest independent national provider of infusion and home care management solutions, today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”), leading independent proxy advisory firms, recommend that BioScrip stockholders vote “FOR” the proposals that are cond...
Increased risk weighs on BIOSCRIP INCO., penalising its rating down t...
The independent financial analyst theScreener just lowered the general evaluation of BIOSCRIP INCO. (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title still shows 3 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date June 14, 2019, the clos...
Key Members of BioScrip’s Leadership Team to Continue in Executive R...
Key Members of BioScrip’s Leadership Team to Continue in Executive Roles with Combined Company Following Close of Option Care Merger DENVER, June 13, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip"), the largest independent national provider of infusion and home care management solutions, today announced that key members of BioScrip’s leadership team will continue in executive roles with the combined company following the close of its pending merger with Option Care Enterprises, Inc. (“Option Care”). Dan Greenleaf, President and Chief Executive Officer of BioScrip, wi...
BioScrip to Participate in Upcoming Investor Conferences
BioScrip to Participate in Upcoming Investor Conferences DENVER, May 21, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that Daniel E. Greenleaf, President and Chief Executive Officer, and Stephen M. Deitsch, Senior Vice President, Chief Financial Officer and Treasurer, will participate in the following upcoming investor conferences: The 16th Annual Craig-Hallum Institutional Investor ConferenceMinneapolis, MinnesotaWednesday, May 29, 2019One-on...
Moody's upgrades BioScrip, Inc.'s Corporate Family Rating to B3, outlo...
Rating Action: Moody's upgrades BioScrip, Inc.' s Corporate Family Rating to B3, outlook stable. Global Credit Research- 14 May 2019. New York, May 14, 2019-- Moody's Investors Service today upgraded the Corporate Family Rating of BioScrip, Inc. to B3 from Caa1 and upgraded the Probability of Default to B3-PD from Caa1-PD.
BioScrip Reports First Quarter 2019 Financial Results
BioScrip Reports First Quarter 2019 Financial Results DENVER, May 02, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its first quarter 2019 financial results. First Quarter 2019 Highlights Net revenue of $179.0 million, up 6.2% compared to $168.6 million in the first quarter of 2018.Net revenue up 7.8% on a billing day rate basis; there was one less billing day in the first quarter of 2019 as compared to the first quart...
BioScrip, Inc. Provides Merger Update
BioScrip, Inc. Provides Merger Update DENVER, April 23, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today provided an update on its proposed merger with Option Care Enterprises, Inc. (“Option Care”). The Company received notification on April 8, 2019, that early termination of the Hart–Scott–Rodino Antitrust Improvements Act of 1976 (“HSR Act”) waiting period has been granted for the Company’s proposed merger with Option Care. The Company expects to file t...
BioScrip Reschedules Release of Fourth Quarter and Full Year 2018 Fina...
BioScrip Reschedules Release of Fourth Quarter and Full Year 2018 Financial Results and Conference Call DENVER, March 13, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the Company has rescheduled the release of its fourth quarter and full year 2018 financial results from Thursday, March 14, 2019 to Friday, March 15, 2019, before the opening of the U.S. financial markets. The Company will also be filing its Form 10-K annual report with the ...
BioScrip Schedules Release of Fourth Quarter and Full Year 2018 Financ...
BioScrip Schedules Release of Fourth Quarter and Full Year 2018 Financial Results and Conference Call DENVER, Feb. 25, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the Company will issue its financial results press release for the fourth quarter and full year ended December 31, 2018 on Thursday, March 14, 2019 before the opening of the U.S. financial markets. Daniel E. Greenleaf, President and Chief Executive Officer, and Stephen Deitsch...
BioScrip to Present at the 37th Annual J.P. Morgan Healthcare Conferen...
BioScrip to Present at the 37th Annual J.P. Morgan Healthcare Conference DENVER, Jan. 03, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that Daniel E. Greenleaf, President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 8:00 a.m. Pacific Time in San Francisco, CA. A live audio webcast of the presentation and copies of materials presented can be accessed via the Comp...
BioScrip to Host Analyst and Investor Day
BioScrip to Host Analyst and Investor Day DENVER, Nov. 26, 2018 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the Company will host an Analyst and Investor Day on Thursday, December 6, 2018 in Reston, Virginia. Daniel E. Greenleaf, President and Chief Executive Officer, will provide an update of the Company’s strategy and business, followed by a fireside chat with members of BioScrip’s executive management team. Presentations will begin at...
BioScrip to Present at the Bank of America Merrill Lynch 2018 Leverage...
BioScrip to Present at the Bank of America Merrill Lynch 2018 Leveraged Finance Conference DENVER, Nov. 20, 2018 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that Daniel E. Greenleaf, President and Chief Executive Officer, and Stephen M. Deitsch, Senior Vice President, Chief Financial Officer and Treasurer, will present at the Bank of America Merrill Lynch 2018 Leveraged Finance Conference on Wednesday, December 5, 2018 at 10:10 a.m. ET at the Boca ...
BioScrip Reports Third Quarter 2018 Financial Results
BioScrip Reports Third Quarter 2018 Financial Results DENVER, Nov. 06, 2018 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its third quarter 2018 financial results. Third Quarter 2018 Highlights Net revenue of $181.0 million, compared to $198.7 million in the third quarter of 2017. Excluding exited UHC therapy line revenue from the prior year quarter, net revenue increased app...
BioScrip Comments on Implementation of Medicare Home Infusion Transit...
BioScrip Comments on Implementation of Medicare Home Infusion Transition Benefit -- Reaffirming Guidance for 2019 Adjusted EBITDA of at least $75 million -- DENVER, Nov. 01, 2018 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the Centers for Medicare and Medicaid Services (“CMS”) published a final rule yesterday afternoon for the implementation of a transitional benefit payment, beginning January 1, 2019, for Medicare Part B home infusion servi...
BioScrip to Present at the 2018 Stephens NY Investment Conference
BioScrip to Present at the 2018 Stephens NY Investment Conference DENVER, Oct. 25, 2018 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that Stephen M. Deitsch, Senior Vice President, Chief Financial Officer and Treasurer, will present at the 2018 Stephens NY Investment Conference on Wednesday, November 7, 2018 at 4:00 p.m. ET at the Lotte New York Palace Hotel. A live webcast of BioScrip’s presentation can be accessed via the Company’s Investor Relat...
BioScrip Schedules Release of Third Quarter 2018 Financial Results and...
BioScrip Schedules Release of Third Quarter 2018 Financial Results and Conference Call DENVER, Oct. 24, 2018 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the Company will issue its financial results press release for the third quarter ended September 30, 2018 on Tuesday, November 6, 2018 before the opening of the U.S. financial markets. Daniel E. Greenleaf, President and Chief Executive Officer, and Stephen Deitsch, Senior Vice President, Ch...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.